Lipid-Based Nanoparticles for Targeted Delivery of Anti-Tubercular Drugs in Pulmonary TB Patients
Article Sidebar
Main Article Content
Abstract
Background: Standard medicine taken by mouth for lung tuberculosis might not work well because it can be harmful to the body and needs to be taken for a long time. Giving medicine directly to the lungs might help it work better where it is needed. Objective: To look at how germs are gone how safe the treatment is, any bad effects and how well people feel in their lungs when using inhaled medicine made with tiny fat particles compared to regular mouth medicine. Methods: This study at one place had 80 adults who had just been diagnosed with having germs in their sputum and had lung tuberculosis. They got either breathing in medicine that had tiny fat particles with isoniazid and rifampicin and less medicine by mouth with pyrazinamide and ethambutol or the regular mouth medicine for six weeks. Data from 75 people was complete. Results: The average time for the germs to go away was shorter in the group that got the treatment than the other group (22.4 ± 4.1 days versus 34.8 ± 5.6 days; difference of -12.4 days; 95% CI -14.7 to -10.1; p<0.001). After six weeks 92.1% and 70.3% of people had no germs in their sputum respectively (p=0.018). At week six the level of ALT was 31.2 ± 5.8 and 54.6 ± 12.3 U/L p<0.001). The group that got the treatment also had better scores for feeling well in their lungs and had fewer stomach problems. Medicine that is inhaled and made with fat particles helped get rid of germs faster and had fewer bad effects, on the body but more studies are needed. Keywords: Administration, Inhalation; Antitubercular Agents; Drug Delivery Systems; Lipids; Nanoparticles; Treatment Outcome; Tuberculosis, Pulmonary
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
1. World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023.
2. Pai M, Kasaeva T, Swaminathan S. Tuberculosis elimination: time to end boiling the frog. Lancet Respir Med. 2022;10(3):223–225.
3. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of drug-susceptible tuberculosis: American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis. 2020;71(1):1–5.
4. D’Ambrosio L, Centis R, Tiberi S, Tadolini M, Dalcolmo M, Zumla A, et al. Adverse drug reactions associated with first- and second-line antituberculosis drugs: recognition, management, and prevention. Eur Respir J. 2020;55(1):1901800.
5. Parumasivam T, Chang RY, Chan HK, Traini D. Dry powder inhalers for pulmonary tuberculosis therapy: state of the art and future perspectives. Adv Drug Deliv Rev. 2021;172:116–138.
6. Patil-Gadhe A, Pokharkar V. Montelukast-loaded nanostructured lipid carriers for pulmonary delivery: formulation, characterization, and in vitro–in vivo evaluation. J Drug Deliv Sci Technol. 2020;57:101734.
7. Truzzi E, Maretti E, Hanuskova M, Leo E, Siligardi C, Sacchetti F, et al. Solid lipid nanoparticles for inhalable delivery of anti-tubercular drugs: formulation and in vitro lung deposition. Int J Pharm. 2022;616:121542.
8. Mehta P, Bothiraja C, Kulkarni A. Inhaled lipid nanoparticles for targeted delivery of rifampicin in pulmonary tuberculosis: formulation, in vitro characterization, and cellular uptake. AAPS PharmSciTech. 2021;22(4):135.
9. Costa A, Sarmento B, Seabra V. Inhalation delivery of lipid-based nanoparticles for pulmonary tuberculosis: overcoming anatomical barriers and cellular targeting. Eur J Pharm Biopharm. 2020;154:218–229.
10. Maretti E, Rossi T, Ligabue G, Ruozi B, Leo E, Croft SL, et al. Inhaled liposomes for local tuberculosis therapy: translational challenges and clinical prospects. Drug Deliv Transl Res. 2021;11(3):912–927.
11. Liang C, Zhang X, Huang Y, Chen Y, Wang W. Inhaled lipid nanoformulations for pulmonary drug delivery: microenvironment interactions and clinical conversion potential. Acta Pharm Sin B. 2022;12(8):3245–3262.
12. Rosalia M, Corvo ML, Saporito F, Sandri G, Rossi S. Liposome-based inhalation therapies: macrophage targeting in infectious lung diseases. Pharmaceutics. 2023;15(2):489.
13. Pham DD, Fattal E, Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment: a review of current formulation strategies and clinical prospects. Int J Pharm. 2021;607:121028.
14. Singh S, Sharma G, Gupta S, Kumar P. Lipid nanoparticles as sustained-release carrier systems for anti-tuberculosis drugs: pharmacokinetics and organ biodistribution. J Control Release. 2020;327:610–622.
15. Machelart A, Willemsen G, Belhaouane I, Deboosere N, Brodin P. Alveolar macrophage targeting with lipid-based nanoparticles enhances intracellular bactericidal activity against Mycobacterium tuberculosis. ACS Nano. 2021;15(10):16210–16223.
16. Sharma R, Yadav S, Kumar A, Prakash O. Drug-induced liver injury in tuberculosis treatment: mechanisms, clinical presentation, and potential prevention strategies. Hepatol Int. 2022;16(4):780–793.
17. Carvalho JT, Silva AC, Santos D, Ferreira H. Dry powder formulations containing lipid nanoparticles for pulmonary application: stability and aerosolization performance. Int J Pharm. 2023;635:122718.
18. Chaudhari P, Shah S, Patel M. Inhaled nanomedicines for respiratory infections: navigating mucociliary clearance and macrophage uptake. Drug Discov Today. 2022;27(9):2510–2521.
19. Fernandez-Maza L, Lopez-Gomez A, Gomez-Mascaraque LG. Biocompatibility and safety evaluation of inhaled lipid nanocarriers in clinical trial frameworks. Toxicol Appl Pharmacol. 2021;426:115632.
20. Gupta A, Khan MA, Siddiqui SA. Particle size and aerodynamic performance of nebulized lipid formulations in target lung delivery: clinical implications. Respir Res. 2023;24(1):102.
21. Structured Abstract